Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 1390620, 7 pages
http://dx.doi.org/10.1155/2016/1390620
Clinical Study

Influence of APOE Genotype on Alzheimer’s Disease CSF Biomarkers in a Spanish Population

1Department of Neurology, University General Hospital of Alicante, Avenida Pintor Baeza 12, 03010 Alicante, Spain
2Genetics Laboratory, University General Hospital of Alicante, Avenida Pintor Baeza 12, 03010 Alicante, Spain
3Immunology Laboratory, University General Hospital of Alicante, Avenida Pintor Baeza 12, 03010 Alicante, Spain
4Department of Preventive Medicine, University General Hospital of Alicante, Avenida Pintor Baeza 12, 03010 Alicante, Spain

Received 6 August 2015; Revised 9 October 2015; Accepted 25 November 2015

Academic Editor: Grazia D’Onofrio

Copyright © 2016 J. A. Monge-Argilés et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. C. Liu, T. Kanekiyo, H. Xu, and G. Bu, “Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy,” Nature Reviews Neurology, vol. 9, no. 2, pp. 106–118, 2013. View at Publisher · View at Google Scholar
  2. G. M. McKhann, D. S. Knopman, H. Chertkow et al., “The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's and Dementia, vol. 7, no. 3, pp. 263–269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. F. H. Duits, C. E. Teunissen, F. H. Bouwman et al., “The cerebrospinal fluid ‘Alzheimer profile’: easily said, but what does it mean?” Alzheimer's & Dementia, vol. 10, no. 6, pp. 713.e2–723.e2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Fagan, M. A. Mintun, A. R. Shah et al., “Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease,” EMBO Molecular Medicine, vol. 1, no. 8-9, pp. 371–380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Engelborghs, K. Sleegers, P. Cras et al., “No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease,” Brain, vol. 130, no. 9, pp. 2320–2326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Lautner, S. Palmqvist, N. Mattsson et al., “Apolipoprotein e genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease,” JAMA Psychiatry, vol. 71, no. 10, pp. 1183–1191, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Leoni, “The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 3, pp. 375–383, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. B. Toledo, H. Zetterberg, A. C. van Harten et al., “Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects,” Brain, vol. 138, no. 9, pp. 2701–2715, 2015. View at Publisher · View at Google Scholar
  9. C. Takizawa, P. L. Thompson, A. Van Walsem, C. Faure, and W. C. Maier, “Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America,” Journal of Alzheimer's Disease, vol. 43, no. 4, pp. 1271–1284, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Artero, R. C. Petersen, J. Touchon, and K. Ritchie, “Revised criteria for mild cognitive impairment: validation within a longitudinal population study,” Dementia and Geriatric Cognitive Disorders, vol. 22, no. 5-6, pp. 465–470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study,” The Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-Y. Wu, R. Delgado, R. Costello, T. Sunderland, R. Dukoff, and G. Csako, “Quantitative assessment of apolipoprotein E genotypes by image analysis of PCR–RFLP fragments,” Clinica Chimica Acta, vol. 293, no. 1-2, pp. 213–221, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Mosconi, S. De Santi, M. Brys et al., “Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints,” Biological Psychiatry, vol. 63, no. 6, pp. 609–618, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. I. Kester, M. A. Blankenstein, F. H. Bouwman, E. J. van Elk, P. Scheltens, and W. M. Van Der Flier, “CSF biomarkers in alzheimer's disease and controls: associations with apoe genotype are modified by age,” Journal of Alzheimer's Disease, vol. 16, no. 3, pp. 601–607, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Popp, P. Lewczuk, I. Frommann et al., “Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype,” Journal of Alzheimer's Disease, vol. 22, no. 2, pp. 459–468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Vemuri, H. J. Wiste, S. D. Weigand et al., “Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease,” Annals of Neurology, vol. 67, no. 3, pp. 308–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Drzezga, T. Grimmer, G. Henriksen et al., “Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease,” Neurology, vol. 72, no. 17, pp. 1487–1494, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka et al., “Cerebrospinal fluid biomarker signature in alzheimer's disease neuroimaging initiative subjects,” Annals of Neurology, vol. 65, no. 4, pp. 403–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. C. Morris, C. M. Roe, C. Xiong et al., “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging,” Annals of Neurology, vol. 67, no. 1, pp. 122–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Fleisher, K. Chen, X. Liu et al., “Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease,” Archives of Neurology, vol. 68, no. 11, pp. 1404–1411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Tosun, N. Schuff, L. M. Shaw, J. Q. Trojanowski, and M. W. Weiner, “Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data,” Journal of Alzheimer's Disease, vol. 26, supplement 3, pp. 77–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. L. G. Apostolova, K. S. Hwang, O. Kohannim et al., “ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease,” NeuroImage: Clinical, vol. 4, pp. 461–472, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Ramírez, W. M. van der Flier, C. Herold et al., “SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and attenuator of cognitive decline in Alzheimer's disease,” Human Molecular Genetics, vol. 23, pp. 6644–6658, 2014. View at Google Scholar
  24. K. Morgen, A. Ramirez, L. Frölich et al., “Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease,” Alzheimer's and Dementia, vol. 10, no. 5, supplement, pp. S269–S276, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Hedskog, J. Brohede, B. Wiehager et al., “Biochemical studies of poly-T variants in the Alzheimer's disease associated TOMM40 gene,” Journal of Alzheimer's Disease, vol. 31, no. 3, pp. 527–536, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Bagnoli, I. Piaceri, A. Tedde et al., “TOMM40 polymorphisms in Italian Alzheimer's disease and frontotemporal dementia patients,” Neurological Sciences, vol. 34, no. 6, pp. 995–998, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Da, J. B. Toledo, J. Zee et al., “Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers,” NeuroImage: Clinical, vol. 4, pp. 164–173, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. B. J. Snider, A. M. Fagan, C. Roe et al., “Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type,” Archives of Neurology, vol. 66, no. 5, pp. 638–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” The Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. R. A. Dean and L. M. Shaw, “Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment,” Clinical Chemistry, vol. 56, no. 1, pp. 7–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Brys, E. Pirraglia, K. Rich et al., “Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment,” Neurobiology of Aging, vol. 30, no. 5, pp. 682–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. N. S. M. Schoonenboom, F. E. Reesink, N. A. Verwey et al., “Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort,” Neurology, vol. 78, no. 1, pp. 47–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman, “Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults,” Archives of Neurology, vol. 64, no. 3, pp. 343–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. R. G. Berenguer, J. A. Monge Argilés, C. M. Ruiz, J. S. Payá, M. A. Blanco Cantó, and C. L. Santana, “Alzheimer disease cerebrospinal fluid biomarkers predict cognitive decline in healthy elderly over 2 years,” Alzheimer Disease and Associated Disorders, vol. 28, no. 3, pp. 234–238, 2014. View at Publisher · View at Google Scholar
  35. K. Blennow, B. Dubois, A. M. Fagan, P. Lewczuk, M. J. De Leon, and H. Hampel, “Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease,” Alzheimer's and Dementia, vol. 11, no. 1, pp. 58–69, 2015. View at Publisher · View at Google Scholar · View at Scopus